🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. 30% Nitrous oxide

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial

  2. 30mg PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial

  3. 400 microgrammes GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  4. 400 µg of MBX 2109 once-weekly by subcutaneous injection

    MBX Biosciences

    Hypoparathyroidism

    phase 2 small molecule active

    1 trial

  5. 413ABM

    BRIGHT MINDS BIOSCIENCES INC.

    MALARIA

    phase 2 other completed

    1 trial

  6. 42 mg transdermal nicotine replacement

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  7. 5 A

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 2 other completed

    1 trial

  8. 5% Bisphosphocin Topical Gel

    Lakewood-Amedex Biotherapeutics

    Chronic Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  9. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  10. 514G3 (2 mg/kg) plus standard IV antibiotic treatment

    XBiotech Germany GmbH

    Staphylococcus Aureus Bacteremia

    phase 2 mab completed

    1 trial

  11. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  12. 6R BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Kidney Disease

    phase 2 small molecule completed

    1 trial

  13. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  14. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Isolated Systolic Hypertension

    phase 2 small molecule terminated

    1 trial

  15. 6R-BH4 (sapropterin dihydrochloride)

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypertension

    phase 2 small molecule completed

    1 trial

  16. A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

    Tyra Biosciences

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

  17. A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial

  18. A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    uniQure biopharma B.V.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 other active

    1 trial

  19. A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  20. A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

    Tyra Biosciences

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  21. AB-101

    Artiva Biotherapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  22. AB-201

    Artiva Biotherapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  23. AB-729

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  24. AB680

    Arcus Biosciences

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources